Acne Vulgaris Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

  • ID: 4451362
  • Report
  • Region: Global
  • 141 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • Realm Therapeutics, Inc.
  • Sol-Gel Technologies Ltd.
  • MORE
Acne vulgaris currently exhibits a growing pipeline with approximately 49 drug candidates.

Positive Clinical Results Supporting the Pipeline Growth

Various drug candidates have shown positive clinical results and are proceeding towards further development. For instance, In May 2017, Foamix Ltd. announced that FMX101 was generally safe and well tolerated with no drug-related serious adverse events from two double-blind, randomized, placebo-controlled Phase III trials for the treatment of moderate-to-severe acne vulgaris. AndroScience Corporation announced that ASC-J9 in a cream formulation demonstrated a therapeutic effect in lowering lesion counts in moderate to severe acne.

Acne Vulgaris Therapeutics Pipeline has moved towards the development of biologicals and peptides

According to the research findings, the drug candidates in acne vulgaris pipeline have move from small molecule towards biologics and peptides. Allergan plc is in the process of manufacturing ANT-1207, also known as botulinum toxin A topical, under the Phase II stage of development for the treatment of acne vulgaris. The therapeutic candidate is an anticholinergic agent, being developed to be administered by topical route. Helix Biomedix, Inc. in a process of developing peptide based molecule, which is in the unknown stage for the treatment of acne vulgaris.

Various Technologies for Targeted Drug Delivery Driving the Growth of the Pipeline

Most of the companies possess advanced technologies for the development of acne vulgaris. For instance, Sol-Gel Technologies Ltd. introduced a technology known as “sol-gel”, in which silica on site forms a microcapsule shells and release drugs at site of action. The drug substance that is added during the sol-gel reaction is encapsulated, through which a core-shell structure is formed. Therefore, the contribution of advanced technologies for making targeted therapies is a key factor driving the growth of acne vulgaris pipeline therapeutics.

Some of the key players developing drugs for the treatment of acne vulgaris therapeutics pipeline include Sol-Gel Technologies Ltd., Realm Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., and Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.).

Acne Vulgaris Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Realm Therapeutics, Inc.
  • Sol-Gel Technologies Ltd.
  • MORE
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Acne Vulgaris Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Acne Vulgaris Therapeutics Pipeline Analysis by Phase (2017)
5.1 Filed: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase III: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase II/III: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.4 Phase II: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.5 Phase I: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.6 Pre-Clinical: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology
5.7 Discovery: Drug profiles
5.4.1 Strategic Development
5.4.2 Designation
5.4.3 Grants
5.4.4 Patent
5.4.5 Technology
5.8 Unknown: Drug profiles

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials, by Region
6.2 Clinical Trials, by Trial Status

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Acne Vulgaris Therapeutics Pipeline
7.2 SWOT Analysis of Acne Vulgaris Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1: Pipeline Analysis Of Acne Vulgaris By Company (2017)
Table 2: Description Of Filed
Table 3: Clinical Trials Of Filed
Table 4: Description Of Phase III
Table 5: Clinical Trials Of Phase III
Table 6: Description Of Phase II/III
Table 7: Clinical Trials Of Phase II/III
Table 8: Description Of Phase II
Table 9: Clinical Trials Of Phase II
Table 10: Description Of Phase I
Table 11: Clinical Trials Of Phase I
Table 12: Description Of Pre-Clinical
Table 13: Description Of Discovery
Table 14: Description Of Unknown
Table 15: Companies - at a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Split Of Primary And Secondary Research
Fig 3: Breakdown Of Primary Research By Industry Participant
Fig 4: Breakdown Of Primary Research By Company Type
Fig 5: Number Of Acne Vulgaris Drug Candidates Under Development (2017)
Fig 6: Acne Vulgaris Pipeline Split, By Molecule Type (2017)
Fig 7: Acne Vulgaris Pipeline Split, By Route Of Administration (2017)
Fig 8: Breakdown Of Clinical Trials, By Region
Fig 9: Breakdown Of Clinical Trials, By Trial Status
Fig 10: Key Players Benchmarking
Fig 11: Swot Analysis
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Promius Pharma, LLC (subsidiary of Dr. Reddy’s Laboratories Ltd.)
  • Realm Therapeutics, Inc.
  • Sienna Biopharmaceuticals, Inc.
  • Sol-Gel Technologies Ltd.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll